A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07619118

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07619118
  • EU CT 2026-526258-15-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07619118. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-10 (actual); primary completion 2027-05-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
Condition
Hypercholesterolaemia
Intervention (Combination product)
laroprovstat/rosuvastatin 1
Intervention (Combination product)
laroprovstat/rosuvastatin 2
Intervention (Combination product)
laroprovstat/rosuvastatin 3
Intervention (Combination product)
laroprovstat/rosuvastatin 4
Intervention (Drug)
Placebo to match laroprovstat/rosuvastatin 1,2,3
Intervention (Drug)
Placebo to match laroprovstat/rosuvastatin 4
Intervention (Drug)
Rosuvastatin 1
Intervention (Drug)
Rosuvastatin 2
Intervention (Drug)
Rosuvastatin 3
Intervention (Drug)
Rosuvastatin 4
Intervention (Drug)
Placebo to match Rosuvastatin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07619118
Content hash
5bd76dbd84c4ad7996c0ff4d87a59ba1c3184c6c6a8ccd2e799cb167053b048a